67 related articles for article (PubMed ID: 31207004)
1. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
2. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Parrish KE; Pokorny J; Mittapalli RK; Bakken K; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2015 Nov; 355(2):264-71. PubMed ID: 26354993
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Effects of Mitoquinone via Cell Cycle Arrest and Apoptosis in Canine Mammary Gland Tumor Cells.
Lee R; Lee WY; Park HJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732133
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis.
Birnhuber A; Egemnazarov B; Biasin V; Bonyadi Rad E; Wygrecka M; Olschewski H; Kwapiszewska G; Marsh LM
Respir Res; 2020 Jul; 21(1):167. PubMed ID: 32616042
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.
Xue Z; Lui VWY; Li Y; Jia L; You C; Li X; Piao W; Yuan H; Khong PL; Lo KW; Cheung LWT; Lee VHF; Lee AWM; Tsao SW; Tsang CM
J Exp Clin Cancer Res; 2020 Nov; 39(1):262. PubMed ID: 33243298
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway.
Zhang Y; He LJ; Huang LL; Yao S; Lin N; Li P; Xu HW; Wu XW; Xu JL; Lu Y; Li YJ; Zhu SL
Clin Transl Med; 2021 Aug; 11(8):e503. PubMed ID: 34459131
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
Zhong N; Yu D; Yang M; Lu X; Zhang Q; Wei W; Jiao J; Yang X; Zhu Z; Chen S; Xiao J
J Cancer Res Clin Oncol; 2024 Feb; 150(2):95. PubMed ID: 38369555
[TBL] [Abstract][Full Text] [Related]
8. HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma.
Shi J; Lv S; Wu M; Wang X; Deng Y; Li Y; Li K; Zhao H; Zhu X; Ye M
Clin Transl Med; 2020 Jan; 10(1):182-198. PubMed ID: 32508030
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib releases the latent differentiation capacity of neuroblastoma cells.
Ferguson KM; Gillen SL; Chaytor L; Poon E; Marcos D; Gomez RL; Woods LM; Mykhaylechko L; Elfari L; Martins da Costa B; Jamin Y; Carroll JS; Chesler L; Ali FR; Philpott A
Dev Cell; 2023 Oct; 58(19):1967-1982.e8. PubMed ID: 37734383
[TBL] [Abstract][Full Text] [Related]
10. Anticancer effect of superoxide dismutase on canine mammary gland tumour in vitro.
Ko BG; An JH; Lee JH; Kim KB; Kim TH; Park SM; Chae HK; Youn HY
Vet Med Sci; 2024 Jan; 10(1):e1323. PubMed ID: 37997503
[TBL] [Abstract][Full Text] [Related]
11. Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells.
Gallanis GT; Sharif GM; Schmidt MO; Friedland BN; Battina R; Rahhal R; Davis JE; Khan IS; Wellstein A; Riegel AT
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980794
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells.
Conroy LR; Lorkiewicz P; He L; Yin X; Zhang X; Rai SN; Clem BF
Cancer Cell Int; 2020; 20():280. PubMed ID: 32624705
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Cell Cycle, RRM2 and NF-κB for the Treatment of Breast Cancers.
Sultana N; Elford HL; Faridi JS
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473336
[TBL] [Abstract][Full Text] [Related]
14. Three-Dimensional Cultivation a Valuable Tool for Modelling Canine Mammary Gland Tumour Behaviour In Vitro.
Huniadi M; Nosálová N; Almášiová V; Horňáková Ľ; Valenčáková A; Hudáková N; Cizkova D
Cells; 2024 Apr; 13(8):. PubMed ID: 38667310
[TBL] [Abstract][Full Text] [Related]
15. Effect of Melatonin on Chemoresistance Exhibited by Spheres Derived from Canine Mammary Carcinoma Cells.
Cataldo D; Aravena G; Escobar A; Tapia JC; Peralta OA; Torres CG
Animals (Basel); 2024 Apr; 14(8):. PubMed ID: 38672378
[TBL] [Abstract][Full Text] [Related]
16. Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins.
Yalcin GD; Mutlu P; Kazan HH; Gunduz U
J Chemother; 2024 Apr; ():1-9. PubMed ID: 38664974
[TBL] [Abstract][Full Text] [Related]
17. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.
Valdivia G; Alonso-Diez Á; Pérez-Alenza D; Peña L
Front Vet Sci; 2021; 8():623800. PubMed ID: 33681329
[TBL] [Abstract][Full Text] [Related]
18. The Carnitine Palmitoyltransferase 1A Inhibitor Teglicar Shows Promising Antitumour Activity against Canine Mammary Cancer Cells by Inducing Apoptosis.
Cacciola NA; Sepe F; Fioriniello S; Petillo O; Margarucci S; Scivicco M; Peluso G; Balestrieri A; Bifulco G; Restucci B; Severino L
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513899
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma.
Setyo LC; Donahoe SL; Shearer PL; Wang P; Krockenberger MB
J Vet Diagn Invest; 2023 Mar; 35(2):109-115. PubMed ID: 36648148
[TBL] [Abstract][Full Text] [Related]
20. Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation.
Maylina L; Kambayashi S; Baba K; Igase M; Mizuno T; Okuda M
J Vet Med Sci; 2023 Jan; 85(1):99-104. PubMed ID: 36450591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
